Dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with AKT inhibitor MK2206 in esophageal carcinoma cells

被引：0
|
作者：
Yu, Hao [1 ]
Shi, Ni [1 ]
Pan, Zui [1 ]
Chen, Tong [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1253
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Effective Targeting of the PI3-K Pathway in CLL with NVP-BEZ235, a Novel Orally Available Dual PI3K/mTOR Inhibitor
    Shehata, Medhat
    Schnabl, Susanne
    Demirtas, Dita
    Tauber, Stefanie
    Hilgarth, Martin
    Bilban, Martin
    Vanura, Katrina
    Porpaczy, Edit
    Fonatsch, Christa
    Stilgenbauer, Stephan
    Schwarzmeier, Josef D.
    Hubmann, Rainer
    Gaiger, Alexander
    Zielinski, Christoph
    Maira, Sauveur-Michel
    Garcia-Echeverria, Carlos
    Hackl, Wolfgang
    Jaeger, Ulrich
    BLOOD, 2008, 112 (11) : 1086 - 1086
  • [42] The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
    Awasthi, Niranjan
    Yen, Peter L.
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2012, 113 (03) : 784 - 791
  • [43] Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines.
    Shoji, K.
    Oda, K.
    Nakagawa, S.
    Ikeda, Y.
    Kuramoto, H.
    Nishida, N.
    Kawana, K.
    Yano, T.
    Kozuma, S.
    Taketani, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Oda, K.
    Shoji, K.
    Nakagawa, S.
    Kashiyama, T.
    Ikeda, Y.
    Miyamoto, Y.
    Tanikawa, M.
    Kuramoto, H.
    Nishida, M.
    Hiraike-Wada, O.
    Yano, T.
    Kozuma, S.
    Taketani, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] PI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells
    Maleka, S.
    Serafin, A. M.
    Akudugu, J. M.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2019, 17 (01): : 37 - 45
  • [46] The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKcs-mediated DNA damage responses
    Mukherjee, Bipasha
    Tomimatsu, Nozomi
    Amancherla, Kaushik
    Camacho, Cristel
    Burma, Sandeep
    CANCER RESEARCH, 2012, 72
  • [47] The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses
    Mukherjee, Bipasha
    Tomimatsu, Nozomi
    Amancherla, Kaushik
    Camacho, Cristel V.
    Pichamoorthy, Nandini
    Burma, Sandeep
    NEOPLASIA, 2012, 14 (01): : 34 - U53
  • [48] Discovery of NVP-BEZ235 - A dual PI3K/mTOR inhibited for targeted cancer treatment
    Garcia-Echeverria, Carlos
    JOURNAL OF BIOMOLECULAR SCREENING, 2008, 13 (07) : 697 - 698
  • [49] The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway
    Luo, Hui
    Yu, Yu-Yu
    Chen, Hong-Mei
    Wu, Wei
    Li, Yong
    Lin, Hong
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (01) : 99 - 106
  • [50] Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma
    Doghman, Mabrouka
    Lalli, Enzo
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2012, 364 (1-2) : 101 - 104
12345